Apollomics Inc.
APLM · XNASCIK 1944885fmd_1C5FC9VTXWQ6WJVK6TYF5VHE0FManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Dec 31, 2025, 9 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 |
| Research and development | 31 | 36 | 35 | 34 | 25 |
| Operating income | – | – | 1 | – | – |
| Interest expense | 0 | 0 | 0 | 0 | 0 |
| Income before taxes | (75) | (95) | (241) | (173) | (54) |
| Income tax expense | (0) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (75) | (95) | (241) | (173) | (54) |
| Net income | (75) | (95) | (241) | (173) | (54) |